99 related articles for article (PubMed ID: 17102098)
21. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
Waldmann J; Fendrich V; Holler J; Buchholz M; Heinmöller E; Langer P; Ramaswamy A; Samans B; Walz MK; Rothmund M; Bartsch DK; Slater EP
Endocr Relat Cancer; 2010 Sep; 17(3):743-56. PubMed ID: 20562231
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
[TBL] [Abstract][Full Text] [Related]
23. Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome.
Lui WO; Chen J; Gläsker S; Bender BU; Madura C; Khoo SK; Kort E; Larsson C; Neumann HP; Teh BT
Oncogene; 2002 Feb; 21(7):1117-22. PubMed ID: 11850829
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD.
Dannenberg H; van Nederveen FH; Abbou M; Verhofstad AA; Komminoth P; de Krijger RR; Dinjens WN
J Clin Oncol; 2005 Mar; 23(9):1894-901. PubMed ID: 15774781
[TBL] [Abstract][Full Text] [Related]
25. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling of benign and malignant pheochromocytoma.
Brouwers FM; Elkahloun AG; Munson PJ; Eisenhofer G; Barb J; Linehan WM; Lenders JW; De Krijger R; Mannelli M; Udelsman R; Ocal IT; Shulkin BL; Bornstein SR; Breza J; Ksinantova L; Pacak K
Ann N Y Acad Sci; 2006 Aug; 1073():541-56. PubMed ID: 17102123
[TBL] [Abstract][Full Text] [Related]
27. Genetic aspects of pheochromocytoma.
Kolačkov K; Tupikowski K; Bednarek-Tupikowska G
Adv Clin Exp Med; 2012; 21(6):821-9. PubMed ID: 23457139
[TBL] [Abstract][Full Text] [Related]
28. Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair.
Blanes A; Sanchez-Carrillo JJ; Diaz-Cano SJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1150-8. PubMed ID: 16394087
[TBL] [Abstract][Full Text] [Related]
29. Expression of c-fos and c-myc proto-oncogenes in human adrenal pheochromocytomas.
Goto K; Ogo A; Yanase T; Haji M; Ohashi M; Nawata H
J Clin Endocrinol Metab; 1990 Feb; 70(2):353-7. PubMed ID: 2405002
[TBL] [Abstract][Full Text] [Related]
30. Analysis of PTEN mutation in non-familial pheochromocytoma.
Puc J; Placha G; Wocial B; Podsypanina K; Parsons R; Gaciong Z
Ann N Y Acad Sci; 2006 Aug; 1073():317-31. PubMed ID: 17102102
[TBL] [Abstract][Full Text] [Related]
31. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas.
Khosla S; Patel VM; Hay ID; Schaid DJ; Grant CS; van Heerden JA; Thibodeau SN
J Clin Invest; 1991 May; 87(5):1691-9. PubMed ID: 2022740
[TBL] [Abstract][Full Text] [Related]
32. A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma.
Cascón A; Ruiz-Llorente S; Rodríguez-Perales S; Honrado E; Martínez-Ramírez A; Letón R; Montero-Conde C; Benítez J; Dopazo J; Cigudosa JC; Robledo M
Genes Chromosomes Cancer; 2005 Mar; 42(3):260-8. PubMed ID: 15609347
[TBL] [Abstract][Full Text] [Related]
33. Distinct expression of galectin-3 in pheochromocytomas.
Gimm O; Krause U; Brauckhoff M; Hoang-Vu C; Dralle H
Ann N Y Acad Sci; 2006 Aug; 1073():571-7. PubMed ID: 17102125
[TBL] [Abstract][Full Text] [Related]
34. Gene copy numbers of erbB oncogenes in human pheochromocytoma.
Sworczak K; Zaczek A; Babinska A; Lisowska U; Bielawski KP; Falkiewicz B
Oncol Rep; 2002; 9(6):1373-8. PubMed ID: 12375051
[TBL] [Abstract][Full Text] [Related]
35. Novel pheochromocytoma susceptibility loci identified by integrative genomics.
Dahia PL; Hao K; Rogus J; Colin C; Pujana MA; Ross K; Magoffin D; Aronin N; Cascon A; Hayashida CY; Li C; Toledo SP; Stiles CD;
Cancer Res; 2005 Nov; 65(21):9651-8. PubMed ID: 16266984
[TBL] [Abstract][Full Text] [Related]
36. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immunoassay and gene expression profiling approaches.
Anouar Y; Yon L; Guillemot J; Thouennon E; Barbier L; Gimenez-Roqueplo AP; Bertherat J; Lefebvre H; Klein M; Muresan M; Grouzmann E; Plouin PF; Vaudry H; Elkahloun AG
Ann N Y Acad Sci; 2006 Aug; 1073():533-40. PubMed ID: 17102122
[TBL] [Abstract][Full Text] [Related]
37. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes.
Moley JF; Brother MB; Fong CT; White PS; Baylin SB; Nelkin B; Wells SA; Brodeur GM
Cancer Res; 1992 Feb; 52(4):770-4. PubMed ID: 1346584
[TBL] [Abstract][Full Text] [Related]
38. Pheochromocytomas: from genetic diversity to new paradigms.
Qin Y; Buddavarapu K; Dahia PL
Horm Metab Res; 2009 Sep; 41(9):664-71. PubMed ID: 19391076
[TBL] [Abstract][Full Text] [Related]
39. Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas.
Herfarth KK; Wick MR; Marshall HN; Gartner E; Lum S; Moley JF
Genes Chromosomes Cancer; 1997 Sep; 20(1):24-9. PubMed ID: 9290950
[TBL] [Abstract][Full Text] [Related]
40. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
Welander J; Söderkvist P; Gimm O
Endocr Relat Cancer; 2011 Dec; 18(6):R253-76. PubMed ID: 22041710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
